Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000
The dual combination of dolutegravir/lamivudine is already included as one of the four recommended as first-line ART in UK guidelines based on several randomised studies (including GEMINI) showing similar efficacy to triple combinations based on second-generation integrase inhibitors.
An oral presentation at HIV Glasgow 2024 added further data supporting similar efficacy and safety results to triple therapy in participants with advanced HIV and CD4 counts <200 cells/mm3, irrespective of baseline CD4 and viral load.
Read the full report by Simon Collins, HIV i-Base here.
All HIV i-Base reports from HIV Glasgow 2024 can be accessed here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.